The aim of this literature review is to summarize and discuss the available evidence for a relationship between polymorphisms in human genes and variability in opioid analgesia and side effects among patients treated for moderate or severe pain. The evidence supporting a role of certain alleles, genotypes or haplotypes in modulation of opioid analgesia is derived from a limited number of studies, a limited number of genes and a limited number of opioids. Although several interesting candidates have emerged as potentially relevant factors, only for one polymorphism, the prevalent 118A>G of the μ-opioid receptor, the accumulated evidence is sufficient to suggest a clinically relevant effect for an opioid used for moderate or severe pain. Still the data are valid only at the group level and cannot be used to predict treatment outcome in individual patients. Only a few of the symptoms often seen as opioid adverse effects in palliative care, such as nausea, vomiting, constipation and sedation, have been associated with genetic variants in various genes, but the results have been based on case reports, healthy volunteers or post-operative patients. So far, there is no clear evidence that genetic markers can be used to predict opioid efficacy or adverse effects in palliative care patients. This reflects the general lack of studies performed in the context of palliative care, the lack of sufficiently scaled studies and the lack of international standards for the assessment of subjective symptoms.
1 WHO. Cancer Pain Relief and Palliative Care. Geneva, Switzerland: World Health Organization, Technical Report Series No 804, 1990.
2.
2 WHO. Cancer pain relief: With a guide to opioid availability.Geneva, Switzerland: World Health Organization, 1996.
3.
3 Hanks GW Conno F Cherny N Hanna M Kalso E McQuay HJ. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer2001; 84: 587–593.
4.
4 Hanks GW Reid C. Contribution to variability in response to opioids. Support Care Cancer2005; 13: 145–152.
5.
5 Cherny N Ripamonti C Pereira J Davis C Fallon M McQuay H. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol2001; 19: 2542–2554.
6.
6 Lander ES Linton LM Birren B Nusbaum C Zody MC Baldwin J. Initial sequencing and analysis of the human genome. Nature2001; 409: 860–921.
7.
7 Venter JC Adams MD Myers EW Li PW Mural RJ Sutton GG. The sequence of the human genome. Science2001; 291: 1304–1351.
8.
8 Stamer UM Bayerer B Stuber F. Genetics and variability in opioid response. European Journal of Pain2005; 9: 101–104.
9.
9 McQuay HJ Carroll D Faura CC Gavaghan DJ Hand CW Moore RA. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther1990; 48: 236–244.
10.
10 Klepstad P Kaasa S Skauge M Borchgrevink PC. Pain intensity and side effects during titration of morphine to cancer patients using a fixed schedule dose escalation. Acta Anaesthesiol Scand2000; 44: 656–664.
11.
11 Stromgren AS Groenvold M Pedersen L Olsen AK Sjogren P. Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer2002; 38: 788–794.
12.
12 Glare P Walsh D Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care2006; 23: 229–235.
13.
13 Mercadante S Villari P Ferrera P Casuccio A. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients. Eur J Pain2006; 10: 153–159.
14.
14 Somogyi AA Barratt DT Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther2007; 81: 429–444.
15.
15 Kasai S Hayashida M Sora I Ikeda K. Candidate gene polymorphisms predicting individual sensitivity to opioids.Naunyn Schmiedebergs Arch Pharmacol. 2007.
16.
16 Lotsch J Skarke C Liefhold J Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet2004; 43: 983–1013.
17.
17 Lotsch J Geisslinger G. Current evidence for a modulation of nociception by human genetic polymorphisms. Pain2007; 132: 18–22.
18.
18 Mogil JS. The genetics of pain. In: JS Mogil, (ed.) Progression in Pain Research and Management. Vol 28. IASP Press; 2004, Seattle, WA, USA.
19.
19 Davis MP Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer2001; 9: 442–451.
21 Stamer UMSF. Genetic factors in pain and its treatment. Current Opinion in Anaesthesiology2007; 20: 478–484.
22.
22 Kilpatrick GJ Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev2005; 25: 521–544.
23.
23 Holthe M Klepstad P Zahlsen K Borchgrevink PC Hagen L Dale O. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol2002; 58: 353–356.
24.
24 Mackenzie PI Miners JO McKinnon RA. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med2000; 38: 889–892.
25.
25 Sawyer MB Innocenti F Das S Cheng C Ramirez J Pantle-Fisher FH. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther2003; 73: 566–574.
26.
26 Holthe M Rakvag TN Klepstad P Idle JR Kaasa S Krokan HE. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J2003; 3: 17–26.
27.
27 Ross JR Rutter D Welsh K Joel SP Goller K Wells AU. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J2005; 5: 324–336.
28.
28 Coulbault L Beaussier M Verstuyft C Weickmans H Dubert L Tregouet D. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther2006; 79: 316–324.
29.
29 Bond C LaForge KS Tian M Melia D Zhang S Borg L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A1998; 95: 9608–9613.
30.
30 Kroslak T Laforge KS Gianotti RJ Ho A Nielsen DA Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem2007; 103: 77–87.
31.
31 Lotsch J Skarke C Grosch S Darimont J Schmidt H Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics2002; 12: 3–9.
32.
32 Skarke C Darimont J Schmidt H Geisslinger G Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther2003; 73: 107–121.
33.
33 Lotsch J Skarke C Wieting J Oertel BG Schmidt H Brockmoller J. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther2006; 79: 72–89.
34.
34 Klepstad P Rakvag TT Kaasa S Holthe M Dale O Borchgrevink PC. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand2004; 48: 1232–1239.
35.
35 Romberg RR Olofsen E Bijl H Taschner PE Teppema LJ Sarton EY. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology2005; 102: 522–530.
36.
36 Chou WY Yang LC Lu HF Ko JY Wang CH Lin SH. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand2006; 50: 787–792.
37.
37 Chou WY Wang CH Liu PH Liu CC Tseng CC Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology2006; 105: 334–337.
38.
38 Oertel BG Schmidt R Schneider A Geisslinger G Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics2006; 16: 625–636.
39.
39 Campa D Gioia A Tomei A Poli P Barale R. Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief.Clin Pharmacol Ther. 2007 [Epub ahead of print]
40.
40 Lotsch J Geisslinger G. Are [mu]-opioid receptor polymorphisms important for clinical opioid therapy. Trends in Molecular Medicine2005; 11: 82–89.
41.
41 Zubieta JK Heitzeg MM Smith YR Bueller JA Xu K Xu Y. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science2003; 299: 1240–1243.
42.
42 Diatchenko L Slade GD Nackley AG Bhalang K Sigurdsson A Belfer I. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet2005; 14: 135–143.
43.
43 Diatchenko L Nackley AG Slade GD Bhalang K Belfer I Max MB. Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain2006; 125: 216–224.
44.
44 Kim H Lee H Rowan J Brahim J Dionne RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain2006; 2: 24.
45.
45 Rakvag TT Klepstad P Baar C Kvam TM Dale O Kaasa S. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain2005; 116: 73–78.
46.
46 Bessler H Shavit Y Mayburd E Smirnov G Beilin B. Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist. Neurosci Lett2006; 404: 154–158.
47.
47 Rees JL Birch-Machin M Flanagan N Healy E Phillips S Todd C. Genetic studies of the human melanocortin-1 receptor. Ann N Y Acad Sci1999; 885: 134–142.
48.
48 Xia Y Wikberg JE Chhajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport1995; 6: 2193–2196.
49.
49 Basbaum AI Fields HL. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci1984; 7: 309–338.
50.
50 Mogil JS Wilson SG Chesler EJ Rankin AL Nemmani KV Lariviere WR. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci U S A2003; 100: 4867–4872.
51.
51 Mogil JS Ritchie J Smith SB Strasburg K Kaplan L Wallace MR. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet2005; 42: 583–587.
52.
52 King M Su W Chang A Zuckerman A Pasternak GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci2001; 4: 268–274.
53.
53 Wandel C Kim R Wood M Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology2002; 96: 913–920.
54.
54 Thompson SJ Koszdin K Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology2000; 92: 1392–1399.
55.
55 Huwyler J Drewe J Klusemann C Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol1996; 118: 1879–1885.
56.
56 Fromm MF Eckhardt K Li SX Schanzle G Hofmann U Mikus G. Loss of analgesic effect of morphine due coadministration of rifampin. Pain1997; 72: 261–267.
57.
57 Kharasch ED Hoffer C Whittington D Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther2003; 74: 543–554.
58.
58 Reyes-Gibby CC Shete S Rakvag T Bhat SV Skorpen F Bruera E. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain2007; 130: 25–30.
59.
59 Hollt V. A polymorphism (A118G) in the mu-opioid receptor gene affects the response to morphine-6-glucuronide in humans. Pharmacogenetics2002; 12: 1–2.
60.
60 Lotsch J; Zimmermann M; Darimont J; Marx C; Dudziak R; Skarke C; . Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity. Anesthesiology 2002; 97: 814–819.
61.
61 Park HJ Shinn HK Ryu SH Lee HS Park CS Kang JH. Genetic Polymorphisms in the ABCB1 Gene and the Effects of Fentanyl in Koreans. Clin Pharmacol Ther2006; 81: 539–546.
62.
62 Strittmatter WJ Saunders AM Schmechel D Pericak-Vance M Enghild J Salvesen GS. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A1993; 90: 1977–1981.
63.
63 Saunders AM Strittmatter WJ Schmechel D George-Hyslop PH Pericak-Vance MA Joo SH. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology1993; 43: 1467–1472.
64.
64 Laskowitz DT Horsburgh K Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab1998; 18: 465–471.
65.
65 Smith JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev2002; 1: 345–365.
66.
66 Packard CJ Westendorp RG Stott DJ Caslake MJ Murray HM Shepherd J. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc2007; 55: 1777–1785.
67.
67 Liang WS Dunckley T Beach TG Grover A Mastroeni D Walker DG. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics2007; 28: 311–322.
68.
68 Kofke WA Blisitt PA Rao H Wang J Addya K Detre J. Remifentanil-induced cerebral blood flow effects in normal humans: Dose and ApoE genotype. Anesthesia and Analgesia2007; 105: 167–175.
69.
69 Riley J Ross JR Rutter D Wells AU Goller K du Bois R. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Supportive Care in Cancer2006; 14: 56–64.
70.
70 Heiskanen T Olkkola KT Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther1998; 64: 603–611.
71.
71 de Leon J Dinsmore L Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol2003; 23: 420–421.
72.
72 Foster A Mobley E Wang Z. Complicated Pain Management in a CYP450 2D6 Poor Metabolizer. Pain Pract2007; 7: 352–356.
73.
73 Susce MT Murray-Carmichael E de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry2006; 30: 1356–1358.
74.
74 Jannetto PJ Wong SH Gock SB Laleli-Sahin E Schur BC Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol2002; 26: 438–447.
75.
75 Jin M Gock SB Jannetto PJ Jentzen JM Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol2005; 29: 590–598.
76.
76 Hirota T Ieiri I Takane H Sano H Kawamoto K Aono H. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos2003; 31: 677–680.
77.
77 Tremblay PB Kaiser R Sezer O Rosler N Schelenz C Possinger K. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol2003; 21: 2147–2155.
78.
78 Kaiser R Tremblay PB Sezer O Possinger K Roots I Brockmoller J. Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics2004; 14: 271–278.
79.
79 Max MB Wu TX Atlas SJ Edwards RR Haythornthwaite JA Bollettino AF. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain2006; 2: 14.
80.
80 Craft RM. Sex differences in opioid analgesia: "from mouse to man". Clin J Pain2003; 19: 175–186.
81.
81 Bernard SA Bruera E. Drug interactions in palliative care. J Clin Oncol2000; 18: 1780–1799.
